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The association of type 2 diabetes with elevated
plasma triglyceride (TG) andvery low-density lipopro-
teins (VLDL), and intrahepatic lipid accumulation
represents a pathophysiological enigma and an un-
met therapeutic challenge. Here, we uncover a link
between insulin action through FoxO1, bile acid (BA)
composition, and altered lipid homeostasis that
brings new insight to this longstanding conundrum.
FoxO1 ablation brings about two signature lipid
abnormalities of diabetes and the metabolic syn-
drome, elevated liver and plasma TG. These changes
are associated with deficiency of 12a-hydroxylated
BAs and their synthetic enzyme,Cyp8b1, that hinders
the TG-lowering effects of the BA receptor, Fxr.
Accordingly, pharmacological activation of Fxr with
GW4064 overcomes the BA imbalance, restoring
hepatic and plasma TG levels of FoxO1-deficient
mice to normal levels. We propose that generation
of 12a-hydroxylated products of BA metabolism
represents a signaling mechanism linking hepatic
lipid abnormalities with type 2 diabetes, and a treat-
ment target for this condition.
INTRODUCTION
The metabolic syndrome and diabetes are linked to abnormali-
ties in lipid metabolism that can lead to cardiovascular disease
and hepatic steatosis (DeFronzo, 2010). This dyslipidemia poses
a double therapeutic challenge: on one hand, its non-LDL based
mechanism renders it poorly responsive to statins and choles-
terol absorption inhibitors; on the other, macrovascular com-
plications arising from it are singularly unresponsive to tight
glycemia control and remain the leading cause of death of dia-
betic patients (National Institute of Diabetes and Digestive and
Kidney Diseases, 2005).
In addition to its role in causing hyperglycemia through exces-
sive glucose production (HGP) (Lin and Accili, 2011), the liver is
also the source of increased triglyceride (TG) levels in diabetes
(Choi and Ginsberg, 2011). Interestingly, the latter antedate the
onset of hyperglycemia, seemingly indicating that alterations of
hepatic TG metabolism are an intrinsic component of the meta-
bolic syndrome (Sørensen et al., 2011).CFoxO1 promotes HGP (Haeusler et al., 2010b; Matsumoto
et al., 2007) and regulates different aspects of liver sensitivity
to insulin. Genetic ablation studies show that FoxO1 is dispens-
able for insulin regulation of hepatic lipidmetabolism (Dong et al.,
2008; Wan et al., 2011). This finding led to a model in which
insulin signaling to glucose and lipid production diverges at
Akt, with FoxO1 regulating HGP, and mTOR or other serine
kinases—such as atypical Pkc—regulating lipid synthesis and
secretion (Biddinger et al., 2008b; Li et al., 2010). However, it
has proven difficult to obtain in vivo evidence for selective insulin
resistance (e.g., for a condition in which FoxO1 signaling is sup-
pressed, but mTOR or Pkc signaling is preserved) (Brown and
Goldstein, 2008; Haeusler and Accili, 2008).
The hypothesis of this work was that FoxO1 mediates aspects
of insulin-dependent hepatic lipidmetabolism that have not been
identified in previous studies because animals were not chal-
lenged appropriately. Using genetic (crosses with low-density
lipoprotein receptor knockout mice, Ldlr/) or dietary ap-
proaches (cholesterol-rich, western-type diet [WTD]) in mice
lacking hepatic FoxO1 (L-FoxO1), we discovered that FoxO1 is
required to suppress hepatic and plasma TG levels through qual-
itative rather than quantitative regulation of BA synthesis.
As potent regulators of hepatic cholesterol and TG metabo-
lism, BAs affect insulin sensitivity and glucose disposal. Bile
acid sequestrants reduce glucose and cholesterol levels in
type 2 diabetics (Staels and Kuipers, 2007). In addition to their
established role in cholesterol and fat absorption as well as
cholesterol detoxification, BAs activate the nuclear receptor
Fxr and the transmembrane receptor Tgr5 (Thomas et al.,
2008). In this work, we show that FoxO1 is required for expres-
sion of a subset of BA synthetic genes and loss of hepatic
FoxO1 results in an unusual BA profile that impairs the ability
of Fxr to reduce TG levels, and can be reversed by pharmacolog-
ical Fxr activation. Our finding that insulin regulates hepatic lipid
metabolism through FoxO1-dependent modulation of BA pro-
files points to alterations of BA composition as an exploitable
opportunity in diabetes therapeutics.RESULTS
Western Diet Exacerbates Lipid Abnormalities in Mice
Lacking Liver FoxO1
We examined liver and plasma lipids in L-FoxO1 and
L-FoxO1:Ldlr/ mice consuming either a regular chow diet or
western diet (WTD). After WTD feeding, weight and adiposity
increased similarly in all groups (data not shown). Livers ofell Metabolism 15, 65–74, January 4, 2012 ª2012 Elsevier Inc. 65
Figure 1. Lipid Parameters after Feeding with Western Diet
(A and B) Livers (A) and hematoxylin and eosin staining (B) of liver sections after
WTD feeding.
(C) Liver weights as a percentage of body weight (n = 7–14).
(D) Liver TG (n = 7–8).
(E and F) Total serum TG (E) and cholesterol (F) in chow andWTD-fed L-FoxO1
and L-FoxO1:Ldlr/ and respective controls after a 5-hr fast (n = 7–12).
(G and H) Ultracentrifuge-fractionated TG (G) and cholesterol (H) in WTD-fed
L-FoxO1:Ldlr/ and controls (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, by
Student’s t-tests. Data are presented as mean ± SEM. See also Figures S1
and S2.
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with larger lipid droplets compared to controls (Figure 1A–1C),
due to a large increase in liver TG content (Figure 1D). In addition,
L-FoxO1:Ldlr/ mice showed significantly higher serum TG
compared to Ldlr/ on both chow and WTD (Figure 1E). The
increase in TG was associated with a large, though not statisti-
cally significant, increase of VLDL-TGs, as assessed by density
ultracentrifugation (Figure 1G). We did not detect a difference
in TG secretion rate (Figure S1A). Total serum cholesterol was66 Cell Metabolism 15, 65–74, January 4, 2012 ª2012 Elsevier Inc.also elevated in fasted L-FoxO1:Ldlr/mice onWTD (Figure 1F),
with trends toward higher LDL- and lower HDL-cholesterol
(Figure 1H).
We also assessed aortic atherosclerotic plaque area in
WTD-fed L-FoxO1:Ldlr/ and controls but found no differences
between the two groups (Figures S1B and S1C). We reckoned
that this unexpected finding of normal plaque size despite
elevated TG and cholesterol might be due to the concurrent
increase in insulin sensitivity of the FoxO1 mutants, as seen
previously in chow-fed mice (Matsumoto et al., 2007). To test
this hypothesis, we measured glucose and insulin levels in
WTD-fed mice. We found that WTD tended to raise both glucose
and insulin, but L-FoxO1 and L-FoxO1: Ldlr/ mice showed
lower fasting glucose and insulin (Figures S2A–S2D) and better
glucose tolerance (Figures S2E–S2H) than littermate controls.
There were no changes in the response to insulin injection
(Figures S2I and S2J). These observations reveal that hepatic
FoxO1 ablation preserves insulin sensitivity of glucose metabo-
lism during WTD, possibly contributing to the lower than ex-
pected plaque size (Tabas et al., 2010).
Despite improvements in glucose metabolism and insulin
sensitivity due to FoxO1 ablation, the elevated serum TG in
L-FoxO1:Ldlr/ mice, as well as the increased liver TG in
WTD-fed L-FoxO1 and L-FoxO1:Ldlr/ mice, resemble key
aspects of the lipid profile of the metabolic syndrome (Isomaa
et al., 2001). These findings could be construed to support
a model in which lipid abnormalities in the metabolic syndrome
arise as a consequence of excessive (or preserved) sensitivity
to the lipogenic actions of insulin (Brown and Goldstein, 2008;
Haeusler and Accili, 2008).
Altered Enterohepatic Bile Acid Composition
in L-FoxO1 Mice
To understand the mechanism underlying the alterations in lipid
levels, we performed comprehensive, unbiased liver metabolite
analyses. Because the liver abnormalities were identical in the
Ldlr-competent and Ldlr-deficient background, we limited sub-
sequent analyses to the former. Notable metabolite changes in
L-FoxO1mice that were consistent with the hypertriglyceridemia
included increases of glycerolipids (data not shown) and very
long-chain fatty acids (FAs) (R20 carbons), with decreases of
some shorter FAs (Figure S3A). However, the most striking
changes were among BA species (Figure 2A). Because BAs
are known to reduce TGs (Lefebvre et al., 2009; Thomas et al.,
2008), we hypothesized that alterations of bile acid metabolism
link FoxO1 deficiency to increased TG levels.
BAs are synthesized in liver from cholesterol in two multi-step
pathways, leading to the formation of primary BAs cholic acid
(CA), chenodeoxycholic acid (CDCA) and, in mice, muricholic
acids (MCAs) (Russell, 2009). After secretion into the duodenum,
these are converted to secondary BAs by microbiota and largely
recycled to the liver (Ridlon et al., 2006). We identified 10 hepatic
BA species with a distinct distribution: in WTD-fed L-FoxO1
mice, all products that had undergone hydroxylation at the
carbon 12 position (12aOH) had relative values less than one,
indicating a decrease compared to controls, a trend that showed
p < 0.05 for T-DCA (Figure 2A, left). Conversely, all products that
had never undergone 12a-hydroxylation had values greater than
one, indicating an increase compared to controls; for T-CDCA
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L-FoxO1 mice, we found that CA, the major 12aOH BA,
showed a trend toward decrease (p = NS), whereas two non-
12a-OH BAs, CDCA and T-CDCA, showed significant increases
(p = 0.001 and 0.03, respectively) (Figure 2A, right). Moreover,
WTD itself increased two non-12a-OH BAs (Figure S3B), sug-
gesting that WTD exacerbates the BA composition defects of
L-FoxO1 mice.
Using LC-MS/MS, we quantitated BAs in gallbladder bile and
feces, as well as the total BA pool inWTD-fedmice (Alnouti et al.,
2008). In every case, L-FoxO1mice showed relative deficiency of
12aOH BAs, leading to a marked increase in the ratios of non-
12a-OH:12a-OH BAs or MCAs:CA (Figures 2B–2D, S3C, and
S3D). However, the total size of the BA pool was unchanged
because an increase in non-12a-OH BAs compensated for the
deficiency (Figure 2E).We also found no difference in conjugated
versus unconjugated BAs (Figure S3E). Quantitation of all
detected BAs is available in Table S1.
FoxO1 Ablation Affects Expression of Bile Acid, Fatty
Acid, and Cholesterol Synthesis Genes
We hypothesized that alterations of the BA pool in FoxO1-
deficient livers reflected altered FoxO1-dependent transcription.
Accordingly, we surveyed gene expression changes using an
unbiased exon microarray approach to identify possible effec-
tors (Table S2). Gene ontology enrichment analyses demon-
strated highly significant changes in lipid metabolism, transport,
storage, and biosynthesis in response to FoxO1 ablation after
WTD feeding (Figure 3A) (Eden et al., 2009).
We saw a striking dysregulation of BA synthesis genes in
L-FoxO1 mice. Consistent with the changes in BA composition,
Cyp8b1, encoding the 12a-hydroxylase enzyme, was sharply
downregulated in all tested conditions (Figures 3B–D), as were
enzymes involved in other steps of BA metabolism, including
Cyp7a1,Cyp27a1,Cyp7b1 (Figures 3B–D, Table S2). Canalicular
cholesterol transporters Abcg5 and Abcg8, two FoxO1 targets
(Biddinger et al., 2008a), were also downregulated, as were the
canalicular bile salt export pump (Bsep) and some sinusoidal
BA uptake transporters (Figures 3B and C, Table S2).
Consistent with their high liver TGs, very long chain FAs, and
glycerolipids, WTD-fed L-FoxO1 (and L-FoxO1:Ldlr/) mice
showed increased expression of genes involved in FA synthesis,
elongation, glycerolipid formation, and lipid storage, including
Fasn, Acly, and Gpam (Figures 3B and 3C, Table S2). However,
these changes occurred in the absence of changes to known
regulators of lipid synthesis and oxidation, including sterol
response element-binding protein (Srebp)-1c and its post-
translational activator Insig-2a (Goldstein et al., 2006), liver X
receptor–a (Lxra, encoded by Nr1h3), and Ppara and its target
genes (Figures 3B and C). Carbohydrate response element-
binding protein (Chrebp) was reduced, but its target Pklr was
unchanged (Table S2). Genes involved in lipoprotein assembly
and turnover—Lpl, Angptl3, Angptl4,Apoc3, andMttp—showed
minor or no changes (Table S2).
Cholesterol biosynthesis genes, such as Hmgcs1, Hmgcr,
and Cyp51, were increased in WTD-fed L-FoxO1 and
L-FoxO1:Ldlr/ mice (Figures 3B and 3C, Table S2). Srebp-2,
which promotes cholesterol biosynthesis genes as well as its
own expression, also tended to be elevated. These findingsCmight be related to the elevated serum cholesterol levels in
L-FoxO1:Ldlr/ mice. Their significance in L-FoxO1 mice will
be discussed below.
Changes in Known Bile Acid Regulators Cannot Explain
the Defects of L-FoxO1 Mice
The observed changes in BAs could potentially explain the alter-
ations of TG and cholesterol homeostasis seen in L-FoxO1mice.
Such changes could arise either as a direct effect of impaired
FoxO1-dependent transcription of BA synthetic enzymes or as
an indirect effect of the FoxO1 knockout on known regulators
of BA synthetic genes. To examine the latter possibility, we
measured expression of nuclear receptors required to regulate
BA synthesis. Hepatic Fxr (encoded by Nr1h4) represses
Cyp7a1 and Cyp8b1 by inducing the nuclear corepressor Shp
(encoded by Nr0b2), which inhibits transcription factor Lrh-1
(encoded by Nr5a2) (Goodwin et al., 2000; Lu et al., 2000).
However, although Fxr and Lrh-1 were expressed normally,
Shp was reduced, as were other Fxr target genes, including
Bsep, Scarb1, and Fetub (Figures 3B and 3C, Table S2). Fxr acti-
vation in the small intestine also represses hepatic Cyp7a1
through Fgf15 and its receptor, Fgfr4 (Chiang, 2009). However,
hepatic Fgfr4 and its cofactor, b-Klotho (encoded by Klb), were
expressed normally. Fgf15 was not expected to be affected
directly by loss of liver FoxO1 because it is made in ileum.
Consistent with this, we found that Fgf15 mRNA tended to be
slightly reduced, although this reduction did not reach statistical
significance. Two intestinal Fxr targets, Ibabp and Shp, also
tended to be reduced (Figure 3E and Table S2). The apparent
reduction of Fxr activity would be expected to result in higher
expression of Cyp7a1 and Cyp8b1. Because we saw the oppo-
site result (Figures 3B and 3D), we conclude that Fxr activity
cannot be directly responsible for the defects in BA synthesis
genes.
We examined other transcriptional regulators of Cyp7a1,
including Lxra, Hnf4a (hepatocyte nuclear factor 4a), Ppara,
Pgc1a (PPARg coactivator 1a), and Rev-erb (encoded by
Nr1d2) (Chiang, 2009), but neither they nor their target genes
were changed (Table S2). Thus, these data support the alterna-
tive hypothesis that reduction of BA synthetic genes is a primary
effect of FoxO1 ablation in L-FoxO1 mice.
Regulation of Bile Acid Synthesis Genes by FoxO1
We next interrogated whether the observed changes in BA
synthetic genes can be imputed to FoxO1. Based on the dearth
of 12a-OH BAs in L-FoxO1 mice, we expected a primary re-
quirement for FoxO1 to promoteCyp8b1. FoxO1 is also reported
to promote Cyp7a1 in rodents (Li et al., 2006; Shin and
Osborne, 2009). We compared single hepatic FoxO1 knockouts
with compound hepatic knockouts of three FoxO isoforms
(L-FoxO1,O3,O4) (Haeusler et al., 2010b). Loss of FoxOs re-
duced the expression of Cyp8b1, Cyp7a1, and Cyp27a1 com-
pared to control littermates, and the reduction in Cyp8b1 tended
to be exacerbated by triple knockout, compared to single FoxO1
knockout (Figure 4A). The changes in Cyp8b1 were identified as
early as post-natal day 2 in neonates (Figure 4B) and, thus, likely
represent primary effects of the FoxO ablation rather than
acquired or compensatory changes (Haeusler et al., 2010b; Mat-
sumoto et al., 2007). In contrast, Cyp7a1, Cyp27a1, and Cyp7b1ell Metabolism 15, 65–74, January 4, 2012 ª2012 Elsevier Inc. 67
Figure 2. Metabolomics and Bile Acid Composition
(A) Hepatic BAs in L-FoxO1mice, relative to controls, on WTD, and chow, separated by origination from 12a-hydroxylation (n = 8). Note that 12-oxo-CDCA does
not have a hydroxyl group at the 12 position, but it is derived by oxidation of CA by bacteria (Ridlon et al., 2006). A complete list of BA abbreviations is available in
Table S4.
(B) 12a-OH (blue) and non-12a-OH (red) BAs, as a percentage of total in gallbladder bile (pooled from 5 mice per genotype), feces (n = 3–4), and total BA pool
(n = 5–6), in WTD-fed L-FoxO1 mice and controls.
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occur later in life (Figure 4B). Although this developmental
snapshot might not adequately capture the complex develop-
mental regulation of BA synthetic genes, the decrease of
Cyp8b1 emerges as a key feature of this model. In fact, when
we examined the nutritional regulation of these genes, we found
only Cyp8b1 to be induced by fasting, in a fashion consistent
with its regulation by FoxO1 (Ga˚fvels et al., 1999). Moreover,
this regulation was lost in L-FoxO1 mice, indicating that FoxO1
is required for Cyp8b1 induction in vivo (Figure 4C).
Finally, we assessed the effect of WTD on these genes.
Cyp7a1 tended to be induced to the same extent in L-FoxO1
and control mice, consistent with an Lxr-mediated effect, in
response to cholesterol contained in the WTD (Kalaany and
Mangelsdorf, 2006) (Figure 4D). Cyp8b1, Cyp27a1 and Cyp7b1
were repressed by WTD (Figure 4D). Thus, it appears that the
physiologic response to WTD entails repression of Cyp8b1
with simultaneous induction of Cyp7a1, the rate-limiting enzyme
of BA synthesis. This combined effect explains the limited rise of
some non-12a-OHBAs in normal mice. In the absence of FoxO1,
the basal deficiency of Cyp8b1 is compounded by the failure to
fully induce Cyp7a1, resulting in the characteristic BA profile of
L-FoxO1 mice.
Lipid Defects in L-FoxO1 Mice Are Secondary
to Impaired Bile Acid Signaling, Not to Altered
Glucose Homeostasis
We hypothesized that lack of 12a-OH BAs renders the BA pool
of L-FoxO1 mice abnormally hydrophilic (Heuman, 1989) and
affects TG metabolism and cholesterol absorption (Lefebvre
et al., 2009). First, we examined TG metabolism. Hydrophobic
BAs are known to reduce TGs (Angelin et al., 1978; Bilz et al.,
2006; Miller and Nestel, 1974; Watanabe et al., 2004), possibly
through the actions of Fxr because Fxr/mice display hypertri-
glyceridemia, whereas Fxr activation reduces TGs (Evans et al.,
2009; Kong et al., 2009; Maloney et al., 2000; Sinal et al., 2000;
Watanabe et al., 2004; Zhang et al., 2006). However, hydrophilic
BAs are unable to activate Fxr (Makishima et al., 1999; Parks
et al., 1999). Thus, the hydrophilic BA pool of L-FoxO1 mice
might explain the reduced Fxr activity.
Wehypothesized that the hypertriglyceridemiaofL-FoxO1mice
was due to low Fxr activity and tested the hypothesis by treating
WTD-fed control and L-FoxO1 mice with low doses of the Fxr
agonist GW4064 (Maloney et al., 2000). This treatment did not
affect body weight (Figure S4A) but was sufficient to activate Fxr,
as shown by the induction of Bsep and the repression of Cyp7a1
and Cyp8b1 (Figure 5A). Although this dose of GW4064 did not
affect liver TG in control mice, liver TG decreased to control levels
in L-FoxO1 mice (Figure 5B). Additionally, we treated mice with
cholic acid (CA), which is known to reduce TGs (Lefebvre et al.,
2009; Watanabe et al., 2004). Consistent with our hypothesis,
CA reduced liver TGs in both control and L-FoxO1mice and elim-
inated differences between genotypes (Figure 5B). GW4064 and
CA had similar effects in L-FoxO1:Ldlr/mice (Figure S4B).(C) Ratio of non-12a-OH BAs to 12a-OH BAs in bile, feces, and total pool.
(D) Composition of total BA pool in WTD-fed L-FoxO1 mice and controls (mean
(E) Quantitation of total BAs, 12a-OH BAs, and non-12a-OH BAs in the total BA p
t-test (A) or Student’s t-tests (B, C, and E). Data are presented as mean ± SEM.
CIn L-FoxO1:Ldlr/ and Ldlr/mice, GW4064 or CA treatment
also reduced serum TGs and eliminated differences between
genotypes (Figure 5C). The decrease occurred primarily, though
not exclusively, in VLDL-TGs (Figures 5C and S4C). Together,
these data support the hypothesis that after WTD feeding,
L-FoxO1 mice develop hypertriglyceridemia due to a dearth of
endogenous Fxr ligands (i.e,. 12a-OH BAs).
Second, we examined cholesterol homeostasis. Absorption of
dietary cholesterol is promoted by hydrophobic, micelle-forming
BAs (Murphy et al., 2005;Wang et al., 2003). Thus, L-FoxO1mice
are expected to be ineffective at absorbing cholesterol, thereby
activating Srebp-2 (Heuman et al., 1989; Murphy et al., 2005).
Furthermore, the effect of WTD on the repression of cholesterol
synthetic genes was blunted in L-FoxO1mice (Table S3), consis-
tent with inefficient Srebp-2 inhibition, providing an explanation
for the inappropriate activation of this pathway (Figures 3B,
3C, and Table S2). Because these effects of BA are Fxr-indepen-
dent, we expected that CA, but not GW4064, would increase
liver cholesterol and normalize cholesterol synthetic genes in
L-FoxO1 mice. Indeed CA, but not GW4064, increased liver
cholesterol and normalized Hmgcs1 in L-FoxO1 mice (Figures
S4D–S4F), although the increase in liver cholesterol after CA
treatment may also cause cellular stress.
Finally, we examined glucose metabolism. We expected that
the improved glucose phenotype of L-FoxO1mice was indepen-
dent of the BA phenotype (Lin and Accili, 2011) because the BA
composition of L-FoxO1 mice predicts worse, not improved,
glycemia (Staels and Kuipers, 2007). To test this, we measured
blood glucose in L-FoxO1 neonates; nursing mothers (Forsyth
et al., 1983) were fed either chow alone or chow containing
0.5% CA. This dose was effective because treated neonates
showed induction of Shp and repression of Cyp8b1 and Cyp7a1
(Figure 5D).
As previously observed (Haeusler et al., 2010b; Matsumoto
et al., 2007), L-FoxO1 neonates from chow-fed mothers showed
hypoglycemia (Figure 5E). After supplementingmothers with CA,
L-FoxO1 neonates still showed hypoglycemia compared to
controls (Figure 5E). Intriguingly, CA treatment slightly elevated
the glycemia of L-FoxO1 neonates but not controls. We pre-
dicted that this may reflect a slight improvement in absorption
of milk, which contains a high percentage of lipid, including
cholesterol (Meier et al., 1965). Consistent with this, cholesterol
synthetic genes were repressed by CA treatment (Figure 5D).
Overall, these data suggest that the regulation of glucosemetab-
olism by FoxO1 is independent of its effect on BA composition.
DISCUSSION
The constellation of metabolic dysfunctions known as the meta-
bolic syndrome includes abnormalities of glucose and lipid
metabolism that are purportedly caused by defective insulin
signaling. The liver is a key site of development of mixed
abnormalities of insulin signaling that affect glucose and lipid
metabolism (Haeusler and Accili, 2008). However, although thevalues of n = 5–6).
ool from WTD-fed mice (n = 5–6). *p < 0.05, **p < 0.01, by Welch’s two-sample
See also Figure S3.
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Figure 3. Gene Expression Changes Due to Hepatic FoxO1 Ablation
(A) Gene ontology enrichment analysis, based on microarrays of liver tissue
from WTD-fed L-FoxO1 and L-FoxO1:Ldlr/ versus littermate controls. Only
nonredundant pathways, where p < 0.001 for the pathway, are shown.
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acterized (Lin and Accili, 2011), its control over TG synthesis,
secretion, and clearance is less defined (Choi and Ginsberg,
2011). In this work we show that insulin signaling through
FoxO1 controls production of 12a-OH BAs and we propose
that these molecules act as regulatory mediators, relaying a
signal from insulin to TG synthesis.
This discovery can be integrated into a new model for the role
of the insulin-Akt-FoxO1 pathway in regulating multiple aspects
of hepatic metabolism (Figure 5F). In normal physiology, FoxO1
maintains the production of 12a-OH BAs by regulating Cyp8b1
and, potentially, other BA synthetic genes. In turn, these BAs
maintain normal Fxr activity, curbing TG levels. In overt diabetes,
FoxO1 becomes trapped inside the nucleus, due to impaired
ability of insulin to cause its nuclear export, compounded by
hyperglycemia (Haeusler et al., 2010a; Kitamura et al., 2005).
In this condition, BAs would become skewed toward excess
12a-OH BAs. Indeed, diabetic models, such as alloxan-treated
rodents, NOD mice, and mice lacking hepatic insulin receptors,
show disproportionately high 12a-OH BAs (Akiyoshi et al.,
1986; Biddinger et al., 2008a; Uchida et al., 1985; Uchida
et al., 1996).
Compellingly, the pattern of increased 12a-OH BAs has also
been identified in human patients with diabetes (Brufau et al.,
2010). Contrary to rodents, however, CDCA—themost abundant
non-12a-OH BA—is hydrophobic and also is the most potent
FXR ligand (Makishima et al., 1999; Parks et al., 1999); thus,
FOXO1 induction of CYP8B1 (which promotes CA formation) at
the expense of CDCA would cause a relative reduction in FXR
activation because CA and its conjugated form T-CA are less
potent FXR ligands (Makishima et al., 1999; Parks et al., 1999).
The constitutive activation of the FOXO1-CYP8B1-12a-OH BA
pathway during diabetes would be expected to result in reduced
FXR activity, raising TG.
Interestingly, L-FoxO1 mice express inadequate Cyp8b1 and
have a distinct functional defect in 12a-hydroxylation; however,
they do not phenocopyCyp8b1/mice (Li-Hawkins et al., 2002;
Murphy et al., 2005). The latter presumably have normal Fxr
activity because they express normal Shp and Bsep, and report-
edly have no steatosis (Li-Hawkins et al., 2002; Murphy et al.,
2005). This is likely due to their compensatory upregulation of
Cyp7a1, which is associated with an expanded BA pool, in-
cluding a substantial increase in CDCA (Li-Hawkins et al., 2002).
In contrast, L-FoxO1mice show low Cyp7a1 andCyp27a1 under
several different conditions and low Cyp7b1 after WTD feeding,
suggesting that FoxO1 is required for full expression of several
of these genes. Mice lacking Lrh-1 specifically in liver show
several similarities to L-FoxO1 mice, including reduced expres-
sion of Cyp8b1 and deficiency of 12-OH BAs (Lee et al., 2008;
Mataki et al., 2007). However, the two models are not identical:
Lrh-1 knockouts express normal levels of Cyp7a1 and they
have not been reported to develop steatosis. The latter may be
attributed to the fact that 1) they have not been challenged with(B–D) Relative hepatic gene expression by qPCR in (B) WTD-fed
L-FoxO:Ldlr/,WTD-fed L-FoxO1 (C), and chow-fed (D) L-FoxO1 mice.
(E) Relative gene expression by qPCR in ileum from WTD-fed L-FoxO1 mice.
(n = 6–7 for all) *p < 0.05, **p < 0.01, ***p < 0.001, by Student’s t-tests. Data are
presented as mean ± SEM.
Figure 4. Regulation of Bile Acid Synthetic Genes
(A) Hepatic gene expression in chow-fed L-FoxO1 and L-FoxO1,O3,O4 mice.
Values are shown relative to same-strain littermate controls (n = 6-8).
(B) Hepatic gene expression from mice sacrificed on postnatal day 2 (P2)
(n = 6).
(C) Hepatic gene expression during a fasting-refeeding time course (n = 5–6).
Mice were fasted up to 24 hr, starting at 8:00 p.m., or fasted 24 hr then refed
chow for 0.25 or 4.25 hr. Black and white boxes at the bottom of each graph
indicate the light/dark cycle.
(D) Comparison of gene expression on chow and WTD (n = 6-7). *p < 0.05,
**p < 0.01, ***p < 0.001, by Student’s t-tests (A–C) or two-way analysis of
variance (D). Data are presented as mean ± SEM.
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Bile Acids and Insulin ActionWTD feeding, and 2) Lrh-1 is reportedly required for full induction
of Fasn, the rate limiting enzyme of FA synthesis (Matsukuma
et al., 2007). This pattern makes L-FoxO1 mice a unique model
of concerted impairment of BA synthesis, creating an environ-
ment that is permissive for the development of hyperlipidemia.
This pattern also suggests that the present phenotype is unlikely
to be due to a single FoxO1 target gene but rather results from the
multiple abnormalities of BA production seen in this model.CPrior observations that gain of FoxO1 function in liver results in
hyperlipidemia (Kamagate et al., 2008; Matsumoto et al., 2006)
seem to be at odds with our current findings, but there are key
differences. Transgenic mice overexpressing FoxO1 become
hyperglycemic, introducing a major confounder (Kamagate
et al., 2008; Nakae et al., 2002). Moreover, acute overexpression
of FoxO1 by adenovirus causes a paradoxical increase in Akt
activity that is seen only rarely in diabetes (Matsumoto et al.,
2006). Therefore, both models subsume independent down-
stream signaling events (e.g., hyperglycemia and Akt activation)
that independently contribute to excess lipid production. In con-
trast, L-FoxO1 mice have improved glycemia and insulin sensi-
tivity, without ancillary Akt activation.
In addition to their role as FXR agonists, BAs also signal
through TGR5. We have not yet explored the consequences of
this model on TGR5 signaling, but there may be effects on other
aspects of the L-FoxO1 phenotype, such as energy expenditure
and metabolic efficiency (Thomas et al., 2008). The present data
raise the possibility that altered BA composition is part of the
underlying pathogenesis of diabetes and that redressing BA
composition may therapeutically benefit a wide population of
patients.
EXPERIMENTAL PROCEDURES
Mice and Diets
Only male mice were studied, with the exception of the experiment in P2 mice,
for which we did not separate male and female neonates. L-FoxO1 and
L-FoxO1,O3,O4mice have been described (Haeusler et al., 2010b;Matsumoto
et al., 2007). L-FoxO1 mice were backcrossed more than 9 generations to
C57BL/6JandcrossedwithLdlr/mice (both fromThe JacksonLaboratories),
exceptmiceused inFigures4A–4C,whichwereonamixedgeneticbackground
(C57BL/6J3 1293 FVB). Mice were fed either standard chow diet (Purina), or
WTD containing 42% kcal from fat and 0.2% cholesterol (TD 88137, Harlan
Teklad), startingat4–7weeksofage.Micewerekepton thediet for10–13weeks
before sacrifice. For GW4064 or CA feeding, mice were fed WTD for
9–10 weeks, then switched to the same WTD, crushed to powder and mixed
with either 0.035% GW4064 (Tocris), or sodium cholate (Sigma): 0.5% for
3 weeks or 1 day (Watanabe et al., 2004) (for liver lipids and gene expression,
respectively in L-FoxO1), or 1% for 1 week (L-FoxO1:Ldlr/). GW4064 treat-
ment in L-FoxO1:Ldlr/mice was delivered by oral gavage, dissolved in corn
oil, at a dose of 18mg/kg/day for 3 days and a final dose of 9mg/kg, 5 hr before
sacrifice.Mice are housed in a 12-hr light/dark cycle, with the dark cycle occur-
ring between 7:00 p.m. and 7:00 a.m. For the time-course experiment shown in
Figure 4C, mice were first synchronized by removing food for 4 hr (12:00 p.m.–
4:00p.m.) and then replacing food for4hr (4:00–8:00p.m.). The24-hr fastbegan
at 8:00 p.m., and mice were sacrificed before the fast (‘‘0’’) and periodically
throughout the fast. Refed mice were refed chow at 8:00 p.m., following the
full 24-hr fast. The light/dark cycle was maintained during this experiment.
Glucose Metabolic Tests
Ad libitum fed measurements were taken between 8:00 a.m. and 10:00 a.m.
and 5 fasted measurements were taken between 1:00 p.m. and 3:00 p.m.,
using OneTouch glucose monitor and strips (Lifescan) and insulin ELISA
(Millipore). Intraperitoneal glucose and insulin tolerance tests were performed
as described (Haeusler et al., 2010b; Nakae et al., 2002). For phosphorylated
Akt analysis, mice were fasted 5 hr, anesthetized, and then injected with 5 mU
of insulin (NovoLog, Novo Nordisk) into the inferior vena cava. Livers were
collected 5 min after injection. Antibodies against total and phospho-Ser473
Akt were from Cell Signaling.
Lipid Metabolic Tests
Tomeasure hepatic lipids, liverswereextractedasdescribed (Folchet al., 1957).
Liverandserum lipidsweremeasuredbycolorimetric assay:TG (Infinity,Thermoell Metabolism 15, 65–74, January 4, 2012 ª2012 Elsevier Inc. 71
Figure 5. Defects in Bile Acid Composition, Lipid, and Glucose Metabolism in L-FoxO1 Mice
(A) Hepatic gene expression showing FXR activation due to GW4064 treatment (n = 6–7).
(B) Liver TGs from L-FoxO1 and control mice fed WTD supplemented with either GW4064 (0.035%) or CA (0.5%) for 3 weeks.
(C) Serum total and VLDL-TGs in L-FoxO1:Ldlr/ and Ldlr/ controls after GW4064 (4 daily treatments, orally) or supplementation of WTD with CA (1% for
1 week). For comparison in B and C, we also show lipid levels frommice fed chow andWTD (without treatment); these are the samemice whose mean values are
shown in Figure 1.
(D and E) Hepatic gene expression (D) and blood glucose levels (E) from P2 neonates, where nursing mothers ate either chow or chow supplemented with CA.
Expression of Cyp8b1 and Cyp7a1 from untreated mice are the same measurements presented in Figure 4B.
(F) Model of metabolic functions of FoxO1 in liver. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, by Student’s t-tests (B, C, and E) or
two-way analysis of variance (A and D). N.S., not significant; HGP, hepatic glucose production. See also Figure S4.
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Bile Acids and Insulin ActionScientific), cholesterol E, and free cholesterol (Wako). Lipoprotein fractionswere
separated by density ultracentrifugation as described (Haeusler et al., 2010a).
Bile Acid Measurements and Metabolomics
A complete list of BA abbreviations is available in Table S4. The metabolomics
study was performed after 10 weeks on chow or WTD. Livers were collected72 Cell Metabolism 15, 65–74, January 4, 2012 ª2012 Elsevier Inc.after a 5-hr fast and snap-frozen. Hepatic BAs (relative values) were measured
by LC-MS/MS (-ESI), with the exception of a-MCA, which was measured by
GC/MS (Metabolon). The relative increase of T-CDCA in L-FoxO1 mice is
underestimated in both WTD and chow-fed mice because it was detectable
in only 4 out of 16 control mice but 12 out of 16 L-FoxO1mice; samples below
the limit of detection were considered to be at the lowest detectable level.
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Bile Acids and Insulin ActionGallbladder bile was collected by syringe from mice fed the WTD for 10 weeks
and pooled (5 per genotype). Fecal samples were collected for two consecu-
tive days following 8 weeks of WTD feeding. For total BA pool, gallbladder and
small intestine were collected together with whole liver, a small piece of which
was used to confirm genotype. For bile, feces, and total BA pool, BAs were
extracted and measured by LC-MS/MS as described (Alnouti et al., 2008).
Detailed methods are provided in Supplemental Information.
Gene Expression
RNA was isolated using TRIzol (Invitrogen). GeneChip Mouse Exon 1.0 ST
Arrays were from Affymetrix. Expression analysis was performed using Partek
Genomics Suite (Partek). For qPCR, cDNA was synthesized using qScript
(QantaBioSciences), and qPCR was performed using SyBr Green (New
England Biolabs). Genes were normalized to 18 S. Primer sequences are
available upon request.
Statistical Analyses
Data are presented as mean ± SEM. Data were analyzed by two-tailed
Student’s t-tests, with the following exceptions: metabolomics data were
analyzed by Welch’s two-sample t-tests; microarray data was analyzed by
analysis of variance (ANOVA), using Partek Genomics Suite; and data com-
paring two variables (Figures 4D, 5A, 5D, S4E, and S4F) were analyzed by
two-way ANOVA; p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article online at
doi:10.1016/j.cmet.2011.11.010.
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